NEW YORK (360Dx) – Qiagen said today that it has submitted its QuantiFeron-TB Gold Plus assay for latent tuberculosis detection to the US Food and Drug Administration for pre-market approval.

The US submission follows on the company's 2016 launch of the CE marked assay in more than 60 countries in Europe, the Middle East, Africa, Asia, and Latin America. More than 600,000 of the tests have been used thus far in those countries, Qiagen said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.